How far should surgeons go? study tests lymph node removal in uterine cancer
NCT ID NCT07306195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 150 women with intermediate- or high-risk endometrial cancer who had surgery to remove the uterus and nearby lymph nodes. Researchers compared removing lymph nodes up to a higher level (near the kidney) versus a lower level (near the pelvis) to see which approach removed more nodes and improved cancer staging. The goal is to find the best surgical method to guide further treatment and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surgical procedure (para-aortic lymphadenectomy)
- What this could lead to
- If successful, this could help determine the best extent of lymph node removal to improve staging and survival in endometrial cancer.
- What could go wrong
- This is a completed study with 150 participants, but results may not apply to all patients. Higher-level dissection may increase surgical risks without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers